Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aptorum Group Ltd Class A stock

Learn how to easily invest in Aptorum Group Ltd Class A stock.

Aptorum Group Ltd Class A is a biotechnology business based in the US. Aptorum Group Ltd Class A shares (APM) are listed on the NASDAQ and all prices are listed in US Dollars. Aptorum Group Ltd Class A employs 26 staff and has a trailing 12-month revenue of around $1.5 million.

How to buy shares in Aptorum Group Ltd Class A

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – APM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aptorum Group Ltd Class A stock price (NASDAQ: APM)

Use our graph to track the performance of APM stocks over time.

Aptorum Group Ltd Class A shares at a glance

Information last updated 2022-09-27.
Latest market close$1.15
52-week range$0.86 - $2.72
50-day moving average $1.45
200-day moving average $1.45
Wall St. target price$15.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.72

Buy Aptorum Group Ltd Class A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aptorum Group Ltd Class A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptorum Group Ltd Class A price performance over time

Historical closes compared with the close of $1.15 from 2022-09-30

1 week (2022-09-23) -1.71%
1 month (2022-09-02) -15.44%
3 months (2022-07-01) -17.86%
6 months (2022-04-01) -27.67%
1 year (2021-10-01) -55.08%
2 years (2020-10-02) -55.43%
3 years (2019-10-02) 16.18
5 years (2017-09-28) N/A

Aptorum Group Ltd Class A financials

Revenue TTM $1.5 million
Gross profit TTM $81,854
Return on assets TTM -36.3%
Return on equity TTM -97.43%
Profit margin 0%
Book value $0.66
Market capitalisation $42.8 million

TTM: trailing 12 months

Aptorum Group Ltd Class A share dividends

We're not expecting Aptorum Group Ltd Class A to pay a dividend over the next 12 months.

Have Aptorum Group Ltd Class A's shares ever split?

Aptorum Group Ltd Class A's shares were split on a 3:1 basis on 1 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Aptorum Group Ltd Class A shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Aptorum Group Ltd Class A shares which in turn could have impacted Aptorum Group Ltd Class A's share price.

Aptorum Group Ltd Class A share price volatility

Over the last 12 months, Aptorum Group Ltd Class A's shares have ranged in value from as little as $0.855 up to $2.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptorum Group Ltd Class A's is 0.0256. This would suggest that Aptorum Group Ltd Class A's shares are less volatile than average (for this exchange).

Aptorum Group Ltd Class A overview

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic.

Frequently asked questions

What percentage of Aptorum Group Ltd Class A is owned by insiders or institutions?
Currently 31.672% of Aptorum Group Ltd Class A shares are held by insiders and 4.429% by institutions.
How many people work for Aptorum Group Ltd Class A?
Latest data suggests 26 work at Aptorum Group Ltd Class A.
When does the fiscal year end for Aptorum Group Ltd Class A?
Aptorum Group Ltd Class A's fiscal year ends in December.
Where is Aptorum Group Ltd Class A based?
Aptorum Group Ltd Class A's address is: 17 Hanover Square, London, United Kingdom, W1S 1BN
What is Aptorum Group Ltd Class A's ISIN number?
Aptorum Group Ltd Class A's international securities identification number is: KYG6096M1069
What is Aptorum Group Ltd Class A's CUSIP number?
Aptorum Group Ltd Class A's Committee on Uniform Securities Identification Procedures number is: G6096M106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site